AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9676069 — intervention group
Group type: COMPARATOR
Intervention: Older Antidepressants (OAs) - NTCA-SSRI group
Number of subjects: 0
Study 9676069 — intervention group
Group type: COMPARATOR
Intervention: Older Antidepressants (OAs) - SSRIs
Number of subjects: 0
Study 7485207 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg BID
Number of subjects: 143
Study 7485207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 2276184 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP vaccine
Number of subjects: 148
Study 2276184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 6243518 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 25 mg
Number of subjects: 10
Study 6243518 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 10
Study 6243518 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 10
Study 6243518 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg
Number of subjects: 10
Study 6243518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31876117 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (once-monthly formulation)
Number of subjects: 587
Study 30576840 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally relevant smartphone-delivered physical activity intervention
Number of subjects: 60
Study 30576840 — intervention group
Group type: COMPARATOR
Intervention: Culturally relevant wellness attention-matched control condition
Number of subjects: 60
Study 28476101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (LSM) using a web-based program (18 individual sessions for 24 weeks)
Number of subjects: 420
Study 28476101 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 420
Study 26015650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin alone (OA) eardrops for 15 days
Number of subjects: 110
Study 26015650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin + dexamethasone combination (ODC) eardrops for 15 days
Number of subjects: 110
Study 24183751 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater depressive symptoms
Number of subjects: 1437
Study 24183751 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor psychosocial functioning
Number of subjects: 1437
Study 24183751 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater symptoms of anxiety
Number of subjects: 1437
Study 24183751 — intervention group
Group type: EXPERIMENTAL
Intervention: Apathy
Number of subjects: 1437
Study 24183751 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative attitudes toward medication
Number of subjects: 1437
Study 24183751 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive symptoms
Number of subjects: 1437
Study 24183751 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication side effects
Number of subjects: 1437
Study 21455872 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fr pancreatic duct stents
Number of subjects: 78
Study 21455872 — intervention group
Group type: COMPARATOR
Intervention: 3-Fr pancreatic duct stents
Number of subjects: 78
Study 18359313 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stents (DESs)
Number of subjects: 360
Study 18359313 — intervention group
Group type: COMPARATOR
Intervention: Bare Metal Stents (BMSs)
Number of subjects: 360
Study 16490807 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 (3 g thrice daily for 2 days) administered 60 minutes after losartan (100 mg) under fed conditions (Treatment C)
Number of subjects: 0
Study 16490807 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 administered 30 minutes prior to losartan (Treatment D)
Number of subjects: 0
Study 16490807 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 administered 30 minutes after losartan (Treatment E)
Number of subjects: 0
Study 16490807 — intervention group
Group type: COMPARATOR
Intervention: Losartan (100 mg) administered alone under fasting conditions (Treatment A)
Number of subjects: 0
Study 16490807 — intervention group
Group type: COMPARATOR
Intervention: Losartan (100 mg) administered alone under fed conditions (Treatment B)
Number of subjects: 0
Study 12880361 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermo-optical behavior measurement using a two-site temperature differential method
Number of subjects: 12
Study 12880361 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification algorithm using a discriminant function
Number of subjects: 12
Study 12167947 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest Multicare Advanced Cleaning dentifrice (polypyrophosphate)
Number of subjects: 0
Study 12167947 — intervention group
Group type: COMPARATOR
Intervention: Industry standard pyrophosphate dentifrice
Number of subjects: 0
Study 1816752 — intervention group
Group type: EXPERIMENTAL
Intervention: PADMA‐28 for 16 weeks
Number of subjects: 50
Study 1816752 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 16 weeks
Number of subjects: 50
Study 30369394 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 0
Study 30369394 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine 100 U/mL (Gla-100)
Number of subjects: 0
Study 30369394 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from Gla-100 to Gla-300
Number of subjects: 0
Study 30369394 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of once-daily insulin injections
Number of subjects: 0
Study 30092651 — intervention group
Group type: EXPERIMENTAL
Intervention: 15° hook plate
Number of subjects: 43
Study 30092651 — intervention group
Group type: COMPARATOR
Intervention: 0° hook plate
Number of subjects: 43
Study 27003376 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic cognitive behaviour therapy (TD‐CBT)
Number of subjects: 145
Study 27003376 — intervention group
Group type: EXPERIMENTAL
Intervention: Disorder‐specific cognitive behaviour therapy (DS‐CBT)
Number of subjects: 145
Study 24378766 — intervention group
Group type: COMPARATOR
Intervention: Ex + PLA (exercise and placebo)
Number of subjects: 34
Study 24378766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex + ISO (exercise and isoflavones)
Number of subjects: 34
Study 22803424 — intervention group
Group type: EXPERIMENTAL
Intervention: Hewei Zhiou Recipe (HZR) combined with ondansetron hydrochloride (OH)
Number of subjects: 80
Study 22803424 — intervention group
Group type: COMPARATOR
Intervention: ondansetron hydrochloride (OH)
Number of subjects: 80
Study 21629372 — intervention group
Group type: EXPERIMENTAL
Intervention: Above-elbow cast
Number of subjects: 85
Study 21629372 — intervention group
Group type: COMPARATOR
Intervention: Below-elbow cast
Number of subjects: 85
Study 17656275 — intervention group
Group type: EXPERIMENTAL
Intervention: Silk sutures
Number of subjects: 60
Study 17656275 — intervention group
Group type: COMPARATOR
Intervention: Nonresorbable multifilament sutures (Supramid, Synthofil, Ethibond Excel, Ti‐cron)
Number of subjects: 60
Study 17656275 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable monofilament Monocryl
Number of subjects: 60
Study 17656275 — intervention group
Group type: COMPARATOR
Intervention: Nonresorbable sutures
Number of subjects: 60
Study 17656275 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable silk and Monocryl
Number of subjects: 60
Study 16200918 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 30
Study 16200918 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 30
Study 11825938 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 719
Study 11825938 — intervention group
Group type: EXPERIMENTAL
Intervention: Picornavirus positive patients
Number of subjects: 719
Study 11825938 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza virus positive patients
Number of subjects: 719
Study 11825938 — intervention group
Group type: EXPERIMENTAL
Intervention: Common respiratory viruses or atypical pathogens
Number of subjects: 719
Study 10365837 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Nd:YAG laser treatment
Number of subjects: 47
Study 10365837 — intervention group
Group type: COMPARATOR
Intervention: Intratumoural injection of 98% alcohol
Number of subjects: 47
Study 7736318 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol treatment (0.5 microgram/day) for 1 month
Number of subjects: 0
Study 7736318 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro CTR treatment (10(‐7) M) of PBMC
Number of subjects: 0
Study 7736318 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro CTR treatment (10(‐7) M) for 48 hours in PBMC from HD patients
Number of subjects: 0
Study 7736318 — intervention group
Group type: COMPARATOR
Intervention: In vitro CTR treatment (10(‐11) and 10(‐9) M)
Number of subjects: 0
Study 7736318 — intervention group
Group type: COMPARATOR
Intervention: Baseline NK cell activity in HD patients
Number of subjects: 0
Study 7736318 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol treatment effect on serum levels
Number of subjects: 0
Study 2407164 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA infusion (Abbott Lifecare)
Number of subjects: 69
Study 2407164 — intervention group
Group type: COMPARATOR
Intervention: Traditional postoperative analgesia (intramuscular or intravenous methods)
Number of subjects: 69
Study 6187790 — intervention group
Group type: EXPERIMENTAL
Intervention: Kallikrein (KK)
Number of subjects: 40
Study 6187790 — intervention group
Group type: COMPARATOR
Intervention: Compound 48/80
Number of subjects: 40
Study 6187790 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 40
Study 30040127 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Next (PN)
Number of subjects: 58
Study 30040127 — intervention group
Group type: COMPARATOR
Intervention: Reciproc (R)
Number of subjects: 58
Study 30040127 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (PN and R)
Number of subjects: 58
Study 30399184 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole of service intervention that diverted people away from hospital and into stepped care psychological therapy clinics
Number of subjects: 642
Study 30399184 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 642
Study 26220327 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation with Proprioceptive Neuromuscular Facilitation (PNF)
Number of subjects: 340
Study 26220327 — intervention group
Group type: EXPERIMENTAL
Intervention: Early rehabilitation with Cognitive Therapeutic Exercise (CTE)
Number of subjects: 340
Study 26220327 — intervention group
Group type: COMPARATOR
Intervention: Delayed rehabilitation with standard protocol
Number of subjects: 340
Study 25204862 — intervention group
Group type: EXPERIMENTAL
Intervention: Caretaker mental health measured by the Self‐Reporting Questionnaire‐20 (SRQ‐20)
Number of subjects: 0
Study 25204862 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent version of the Strengths and Difficulties Questionnaire (SDQ)
Number of subjects: 0
Study 22971472 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparator (COMP, 100% probability of receiving active medication)
Number of subjects: 0
Study 22971472 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled (PC, 50% probability of receiving active medication)
Number of subjects: 0
Study 22971472 — intervention group
Group type: EXPERIMENTAL
Intervention: Both COMP and PC conditions (active medication)
Number of subjects: 0
Study 20429673 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene (daily doses)
Number of subjects: 0
Study 17995971 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol, daily doses of 3 mg kg(‐1) for infants (28 days to 23 months)
Number of subjects: 41
Study 15669893 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg/day
Number of subjects: 311
Study 15669893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study 12957443 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy with bucindolol
Number of subjects: 2708
Study 12957443 — intervention group
Group type: COMPARATOR
Intervention: Diabetes presence
Number of subjects: 2708
Study 10098755 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with non‐metastatic breast cancer at first diagnosis
Number of subjects: 0
Study 10098755 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with soft‐tissue metastases without evidence of skeletal metastases
Number of subjects: 0
Study 10830013 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine
Number of subjects: 93
Study 1816137 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% azelaic acid cream
Number of subjects: 329
Study 1816137 — intervention group
Group type: COMPARATOR
Intervention: 4% hydroquinone cream
Number of subjects: 329
Study 7136329 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and Neomycin with low residue diet and orthograde cleaning of the bowel
Number of subjects: 0
Study 7136329 — intervention group
Group type: COMPARATOR
Intervention: Previous regimen (not specified)
Number of subjects: 0
Study 30573715 — intervention group
Group type: EXPERIMENTAL
Intervention: K+T+A (1 tablet of Ketorolac 10 mg plus 1 capsule of Tramadol 37.5 mg/acetaminophen 325 mg)
Number of subjects: 52
Study 30573715 — intervention group
Group type: COMPARATOR
Intervention: K (1 tablet of Ketorolac 10 mg plus 1 placebo capsule)
Number of subjects: 52
Study 30573715 — intervention group
Group type: EXPERIMENTAL
Intervention: K+T+A
Number of subjects: 52
Study 30573715 — intervention group
Group type: EXPERIMENTAL
Intervention: K+T+A and K
Number of subjects: 52
Study 30365591 — intervention group
Group type: EXPERIMENTAL
Intervention: SB206 12% QD
Number of subjects: 108
Study 30365591 — intervention group
Group type: EXPERIMENTAL
Intervention: SB206 (4% QD, 4% BID, 8% QD, 12% QD)
Number of subjects: 108
Study 30365591 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 108
Study 27429803 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Mixture (VSL#3)
Number of subjects: 82
Study 27429803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 24619298 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice daily
Number of subjects: 36
Study 24619298 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sorafenib 400 mg bid with IV carboplatin (AUC 6) and IV paclitaxel 175 mg/m2 (S+C/T) every 3 weeks
Number of subjects: 36
Study 22395880 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical signs of infectious keratitis assessed by cornea specialists
Number of subjects: 80
Study 22395880 — intervention group
Group type: EXPERIMENTAL
Intervention: Gram stain, genus, and species identification
Number of subjects: 80
Study 22395880 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of irregular/feathery border
Number of subjects: 80
Study 22395880 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of wreath infiltrate or epithelial plaque
Number of subjects: 80
Study 19563257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (various dosages over 14 days)
Number of subjects: 48
Study 17720661 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir with low-dose ritonavir (DRV/r)
Number of subjects: 697
Study 17720661 — intervention group
Group type: COMPARATOR
Intervention: Control PI (almost all ritonavir boosted)
Number of subjects: 697
Study 15871609 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diclofenac sodium (50 mg tablets, twice a day for 14 days)
Number of subjects: 36
Study 15871609 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac (16 mg/ml, 10 drops 4 times a day for 14 days)
Number of subjects: 36
Study 15871609 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both interventions
Number of subjects: 36
Study 11916233 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily
Number of subjects: 22000
Study 11916233 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg daily
Number of subjects: 22000
Study 9723150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (12 weeks treatment)
Number of subjects: 21
Study 9723150 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12 weeks treatment)
Number of subjects: 21
Study 9723150 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients with severe pressure hyperalgesia
Number of subjects: 21
Study 9723150 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients with severe non-somatic depressive symptoms
Number of subjects: 21
Study 9723150 — intervention group
Group type: COMPARATOR
Intervention: Normal volunteers
Number of subjects: 21
Study 7584284 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice at writing target names
Number of subjects: 0
Study 7584284 — intervention group
Group type: COMPARATOR
Intervention: Reading target names
Number of subjects: 0
Study 7584284 — intervention group
Group type: EXPERIMENTAL
Intervention: More frequent practice trials
Number of subjects: 0
Study 2508583 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN (Total Parenteral Nutrition)
Number of subjects: 12
Study 2508583 — intervention group
Group type: COMPARATOR
Intervention: ENT (Enteral Feedings)
Number of subjects: 12
Study 826236 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose only
Number of subjects: 23
Study 826236 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids only
Number of subjects: 23
Study 826236 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of glucose and amino acids
Number of subjects: 23
Study 31483662 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with Bevacizumab
Number of subjects: 132
Study 31483662 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy without Bevacizumab
Number of subjects: 132
Study 28440872 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure and lay health educator (LHE) outreach (print + LHE)
Number of subjects: 348
Study 28440872 — intervention group
Group type: COMPARATOR
Intervention: Brochure (print)
Number of subjects: 348
Study 25939332 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of pregabalin 300 mg hard capsules
Number of subjects: 40
Study 25939332 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of pregabalin 300 mg hard capsules
Number of subjects: 40
Study 23945406 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean red ginseng (6 g daily for 12 weeks)
Number of subjects: 68
Study 23945406 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 68
Study 22048221 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg clopidogrel + PA32540 followed by 75 mg clopidogrel + PA32540 on days 2-7
Number of subjects: 30
Study 22048221 — intervention group
Group type: EXPERIMENTAL
Intervention: PA32540 in the morning + 300 mg clopidogrel 10 h later on day 1 and PA32540 in the morning + 75 mg clopidogrel 10 h later on days 2-7
Number of subjects: 30
Study 22048221 — intervention group
Group type: COMPARATOR
Intervention: 300 mg clopidogrel + 325 mg ECASA followed by 75 mg clopidogrel + 325 mg ECASA on days 2-7
Number of subjects: 30
Study 19218294 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (50 mg/day)
Number of subjects: 29133
Study 16113579 — intervention group
Group type: EXPERIMENTAL
Intervention: Oronasopharyngeal suction (ONPS)
Number of subjects: 140
Study 16113579 — intervention group
Group type: COMPARATOR
Intervention: No suction
Number of subjects: 140
Study 12850527 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 0
Study 10815450 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional education program for children
Number of subjects: 0
Study 8771623 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone substitution
Number of subjects: 0
Study 8771623 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 8771623 — intervention group
Group type: COMPARATOR
Intervention: Amenorrheic women
Number of subjects: 0
Study 8771623 — intervention group
Group type: COMPARATOR
Intervention: Normally menstruating women
Number of subjects: 0
Study 1462974 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2982387 — intervention group
Group type: EXPERIMENTAL
Intervention: etomidate 0.3 mg kg‐1
Number of subjects: 12
Study 2982387 — intervention group
Group type: COMPARATOR
Intervention: thiopentone 5 mg kg‐1
Number of subjects: 12
Study 31033527 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenazopyridine 200 mg on postoperative day 1
Number of subjects: 152
Study 31033527 — intervention group
Group type: COMPARATOR
Intervention: No additional phenazopyridine
Number of subjects: 152
Study 31829274 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.4 μg/kg/h, increased by 0.2 μg/kg/h per hour up to 0.8 μg/kg/h; neonates: 0.2 μg/kg/h, increased by 0.1 μg/kg/h per hour up to 0.4 μg/kg/h)
Number of subjects: 154
Study 31829274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 29994994 — intervention group
Group type: EXPERIMENTAL
Intervention: Aδ fiber activation through CO2 laser delivered ultrafast short constant-temperature heat pulses
Number of subjects: 0
Study 29994994 — intervention group
Group type: COMPARATOR
Intervention: C fiber activation through CO2 laser delivered ultrafast short constant-temperature heat pulses
Number of subjects: 0
Study 27373542 — intervention group
Group type: EXPERIMENTAL
Intervention: Home insertion of etonogestrel implant
Number of subjects: 37
Study 27373542 — intervention group
Group type: COMPARATOR
Intervention: Office insertion of etonogestrel implant
Number of subjects: 37
Study 27373542 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits
Number of subjects: 37
Study 27373542 — intervention group
Group type: COMPARATOR
Intervention: Office visits
Number of subjects: 37
Study 24642719 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index (GI) diet advice
Number of subjects: 621
Study 24642719 — intervention group
Group type: COMPARATOR
Intervention: Control group (no low GI advice)
Number of subjects: 621
Study 22614150 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) supplementation (1 g/kg loading dose and 0.17 g/kg every 6 minutes)
Number of subjects: 6
Study 22614150 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) supplementation (equal volume of saccharin and aspartame solution)
Number of subjects: 6